Filip Dubovsky - 05 Nov 2023 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role: President, R&D
Signature: /s/ John A. Herrmann III, Attorney-in-Fact
Issuer symbol: NVAX
Transactions as of: 05 Nov 2023
Net transactions value: +$5,104
Form type: 4
Filing time: 07 Nov 2023, 17:30:08 UTC
Previous filing: 19 Sep 2023
Next filing: 18 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVAX	Common Stock	Options Exercise	$9,884	+1,400	+2.7%	$7.06	52,994	05 Nov 2023	Direct	F1
transaction	NVAX	Common Stock	Tax liability	$4,780	-677	-1.3%	$7.06	52,317	05 Nov 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NVAX	Restricted Stock Units	Options Exercise	$0	-1,400	-100%	$0.000000^*	0	05 Nov 2023	Common Stock	1,400		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs").
F2	Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F3	The RSUs subject to this grant under the Plan vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the November 5, 2020 grant date, in each case subject to continued employment with the Company through such vesting date.